glp 1 agonist brand names india Glenmark launches biosimilar of anti-diabetic drug, liraglutide in 2025’s Breakthrough GLP-1 Obesity Treatments:
Description
2023;6(5):e2314493
Censani M, Chin VL, Fennoy I
Yaribeygi H, Farrokhi FR, Abdalla MA, et al
The global respective SURMOUNT study program comprises four randomized controlled trials with a study duration of at least 72 weeks using the tirzepatide doses of 10 and 15 mg in the studies SURMOUNT-2 to SURMOUNT-4 and all three doses, including the 5-mg dose in SURMOUNT-1 (8285)
The grey market carries significant risks and should be approached with extreme caution
Participants taking tirzepatide lost an average of 15.3% of their body weight after a year, while those on semaglutide lost about 8.3%
